145 related articles for article (PubMed ID: 23402021)
1. Targeting gC1qR domains for therapy against infection and inflammation.
Ghebrehiwet B; Jesty J; Vinayagasundaram R; Vinayagasundaram U; Ji Y; Valentino A; Tumma N; Hosszu KH; Peerschke EI
Adv Exp Med Biol; 2013; 735():97-110. PubMed ID: 23402021
[TBL] [Abstract][Full Text] [Related]
2. gC1qR/p33 serves as a molecular bridge between the complement and contact activation systems and is an important catalyst in inflammation.
Ghebrehiwet B; CebadaMora C; Tantral L; Jesty J; Peerschke EI
Adv Exp Med Biol; 2006; 586():95-105. PubMed ID: 16893067
[TBL] [Abstract][Full Text] [Related]
3. The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)
Ghebrehiwet B; Geisbrecht BV; Xu X; Savitt AG; Peerschke EIB
Semin Immunol; 2019 Oct; 45():101338. PubMed ID: 31744753
[TBL] [Abstract][Full Text] [Related]
4. Structure-function studies using deletion mutants identify domains of gC1qR/p33 as potential therapeutic targets for vascular permeability and inflammation.
Ghebrehiwet B; Jesty J; Xu S; Vinayagasundaram R; Vinayagasundaram U; Ji Y; Valentino A; Hosszu KK; Mathew S; Joseph K; Kaplan AP; Peerschke EI
Front Immunol; 2011 Nov; 2():. PubMed ID: 22282702
[TBL] [Abstract][Full Text] [Related]
5. Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore).
Pixley RA; Espinola RG; Ghebrehiwet B; Joseph K; Kao A; Bdeir K; Cines DB; Colman RW
Thromb Haemost; 2011 Jun; 105(6):1053-9. PubMed ID: 21544310
[TBL] [Abstract][Full Text] [Related]
6. The contribution of gC1qR/p33 in infection and inflammation.
Peerschke EI; Ghebrehiwet B
Immunobiology; 2007; 212(4-5):333-42. PubMed ID: 17544818
[TBL] [Abstract][Full Text] [Related]
7. The plasma bradykinin-forming pathways and its interrelationships with complement.
Kaplan AP; Ghebrehiwet B
Mol Immunol; 2010 Aug; 47(13):2161-9. PubMed ID: 20580091
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
9. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein.
Dedio J; Jahnen-Dechent W; Bachmann M; Müller-Esterl W
J Immunol; 1998 Apr; 160(7):3534-42. PubMed ID: 9531316
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells.
Joseph K; Ghebrehiwet B; Kaplan AP
Clin Immunol; 1999 Sep; 92(3):246-55. PubMed ID: 10479529
[TBL] [Abstract][Full Text] [Related]
11. Factor XII and kininogen asymmetric assembly with gC1qR/C1QBP/P32 is governed by allostery.
Kaira BG; Slater A; McCrae KR; Dreveny I; Sumya U; Mutch NJ; Searle M; Emsley J
Blood; 2020 Oct; 136(14):1685-1697. PubMed ID: 32559765
[TBL] [Abstract][Full Text] [Related]
12. gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema.
Fandaros M; Joseph K; Kaplan AP; Rubenstein DA; Ghebrehiwet B; Yin W
Inflammation; 2022 Feb; 45(1):116-128. PubMed ID: 34494203
[TBL] [Abstract][Full Text] [Related]
13. The C1q and gC1qR axis as a novel checkpoint inhibitor in cancer.
Ghebrehiwet B; Zaniewski M; Fernandez A; DiGiovanni M; Reyes TN; Ji P; Savitt AG; Williams JL; Seeliger MA; Peerschke EIB
Front Immunol; 2024; 15():1351656. PubMed ID: 38711524
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor-2 (TFPI-2) recognizes the complement and kininogen binding protein gC1qR/p33 (gC1qR): implications for vascular inflammation.
Peerschke EI; Petrovan RJ; Ghebrehiwet B; Ruf W
Thromb Haemost; 2004 Oct; 92(4):811-9. PubMed ID: 15467913
[TBL] [Abstract][Full Text] [Related]
15. Formation of bradykinin: a major contributor to the innate inflammatory response.
Joseph K; Kaplan AP
Adv Immunol; 2005; 86():159-208. PubMed ID: 15705422
[TBL] [Abstract][Full Text] [Related]
16. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor.
Lim BL; Reid KB; Ghebrehiwet B; Peerschke EI; Leigh LA; Preissner KT
J Biol Chem; 1996 Oct; 271(43):26739-44. PubMed ID: 8900153
[TBL] [Abstract][Full Text] [Related]
17. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection.
Ghebrehiwet B; Lim BL; Kumar R; Feng X; Peerschke EI
Immunol Rev; 2001 Apr; 180():65-77. PubMed ID: 11414365
[TBL] [Abstract][Full Text] [Related]
18. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells.
Mahdi F; Shariat-Madar Z; Todd RF; Figueroa CD; Schmaier AH
Blood; 2001 Apr; 97(8):2342-50. PubMed ID: 11290596
[TBL] [Abstract][Full Text] [Related]
19. Interaction of high molecular weight kininogen binding proteins on endothelial cells.
Joseph K; Tholanikunnel BG; Ghebrehiwet B; Kaplan AP
Thromb Haemost; 2004 Jan; 91(1):61-70. PubMed ID: 14691569
[TBL] [Abstract][Full Text] [Related]
20. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease.
Joseph K; Shibayama Y; Nakazawa Y; Peerschke EI; Ghebrehiwet B; Kaplan AP
Immunopharmacology; 1999 Sep; 43(2-3):203-10. PubMed ID: 10596854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
